|
|
Article: Baxter to distribute treatment for antithrombin III deficiency in U.S. (Baxter Healthcare Corp., ATnativ Antithrombin III)
- Article from:
- PR Newswire
- Article date:
- June 19, 1990
CopyrightCOPYRIGHT 1990 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BAXTER TO DISTRIBUTE TREATMENT FOR ANTITHROMBIN III DEFICIENCY IN U.S.
GLENDALE, Calif., June 19 /PRNewswire/ -- Baxter Healthcare Corporation, Hyland division, today announced an agreement with Kabi Vitrum AB to distribute ATnativ Antithrombin III (Human) Heat treated, in the United States. ATnativ is indicated for treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures, or when they suffer from thomboembolism.
ATnativ, licensed under orphan drug status, received approval for marketing by the U.S. Food and Drug Administration in December 1989. It has been available in several European ...